

1 **Title:** SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing
2 antibodies and increase during convalescence.

3 **Short Title:** SARS-CoV-2-specific peripheral T follicular helper cells

4 **Authors:** Sushma Boppana¹⁺, Kai Qin¹⁺, Jacob K Files¹, Ronnie M. Russell^{2,3}, Regina Stoltz²,
5 Frederic Bibollet-Ruche^{2,3}, Anju Bansal¹, Nathan Erdmann¹, Beatrice H. Hahn^{2,3}, Paul Goepfert^{1*}

6 **Affiliations:**

7 ¹Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham,
8 Birmingham, AL 35294, USA; ²Department of Medicine, University of Pennsylvania, Philadelphia,
9 PA; ³Department of Microbiology, University of Pennsylvania, Philadelphia, PA

10 ⁺These authors contributed equally.

11 ***Corresponding author:** Paul Goepfert, Bevill Biomedical Research Building Rm 563, 845 19th
12 Street S, Birmingham, AL 35294, USA; pgoepfert@uabmc.edu; ORCID 0000-0001-8441-5737

13 **Abstract:** T-cell immunity is likely to play a role in protection against SARS-CoV-2 by helping
14 generate neutralizing antibodies. We longitudinally studied CD4 T-cell responses to the M, N, and
15 S structural proteins of SARS-CoV-2 in 21 convalescent individuals. Within the first two months
16 following symptom onset, a majority of individuals (81%) mount at least one CD4 T-cell response,
17 and 48% of individuals mount detectable SARS-CoV-2-specific peripheral T follicular helper cells
18 (pTfh, defined as CXCR5⁺PD1⁺ CD4 T cells). SARS-CoV-2-specific pTfh responses across all
19 three protein specificities correlate with antibody neutralization with the strongest correlation
20 observed for S protein-specific responses. When examined over time, pTfh responses increase
21 in frequency and magnitude in convalescence, and robust responses with magnitudes greater
22 than 5% were detected only at the second convalescent visit, an average of 38 days post-
23 symptom onset. These data deepen our understanding of antigen-specific pTfh responses in
24 SARS-CoV-2 infection, suggesting that M and N protein-specific pTfh may also assist in the
25 development of neutralizing antibodies and that pTfh response formation may be delayed in
26 SARS-CoV-2 infection.

27 **Word counts:** Abstract, 172; Author summary, 170; Main text, 4212

28 **Key words:** SARS-CoV-2; COVID-19; peripheral T follicular helper cell; antigen-specific T-cell
29 responses; neutralizing antibodies; convalescence

30

31 **Author Summary:** Since December 2019, the Coronavirus Disease 2019 (COVID-19) pandemic
32 has caused significant morbidity and mortality worldwide. Most currently licensed vaccines are
33 understood to protect against infection by inducing neutralizing antibodies. As such, ongoing
34 COVID-19 vaccine trials have focused on antibody neutralization as a primary immunologic
35 endpoint. It is well established that T follicular helper cells are essential to the development of
36 neutralizing antibodies and that a subset of these cells, peripheral T follicular helper cells (pTfh),
37 can be studied in the blood. However, little is known about Tfh responses mounted in SARS-CoV-
38 2 infection. Here, we studied pTfh to three major structural proteins in individuals recovered from
39 COVID-19. We find that SARS-CoV-2-specific pTfh frequencies correlate with neutralizing
40 antibody responses, especially those directed against the spike protein. We also find that pTfh
41 responses to SARS-CoV-2 increase over time. Our findings suggest that pTfh responses against
42 proteins other than the spike protein may contribute to the development of neutralizing antibodies
43 and suggests that formation of pTfh responses in SARS-CoV-2 infection may be delayed.

44 **Introduction**

45 Cases of COVID-19, caused by the novel severe acute respiratory syndrome coronavirus
46 2 (SARS-CoV-2), were first reported in Wuhan, China at the end of 2019 (1). Since then, the
47 COVID-19 pandemic has caused significant morbidity, mortality, and economic disruption
48 worldwide (2). In SARS-CoV-2 infection, initial studies reported significant lymphopenia in
49 hospitalized patients (3). An elevation of both activation and exhaustion markers on T cells in both
50 severe and mild disease has also been described (4-6). More recently, data on antigen-specific
51 T-cell responses in individuals recovered from SARS-CoV-2 infection has emerged. These
52 studies have reported CD4 T-cell responses to SARS-CoV-2 in 80-100% of convalescent
53 individuals, with most publications focusing on the Spike (S) protein (7-10).

54 Several SARS-CoV-2 vaccine efficacy trials are in progress, and recent Phase I/II trial
55 data have highlighted the presence of neutralizing antibodies as evidence of plausible vaccine
56 efficacy (11-13). Although the key components of a protective immune response against SARS-
57 CoV-2 remain unclear, studies in non-human primates have found that neutralizing antibodies
58 (nAb) are a correlate of protection in infection and vaccination (14, 15). With this in mind, a better
59 understanding of how T-cell responses contribute to the formation of nAb is critical to optimizing
60 future vaccine design.

61 Because direct study of lymphoid tissues in humans is difficult, peripheral T follicular cells
62 (pTfh), or T follicular helper cells (Tfh) circulating in the blood, serve as an important surrogate for
63 understanding Tfh responses within germinal centers. While there is some controversy regarding
64 how to best identify these cells, there is general consensus that these cells express CXCR5, a
65 lymph node homing receptor, and many groups use PD1 expression in conjunction with CXCR5
66 to define pTfh (16-18). While frequencies of circulating CXCR5⁺PD1⁺ CD4 T cells are typically
67 low, these cells are closely linked to Tfh in lymphoid tissue (19) and have been shown to support
68 humoral responses (20, 21). Antigen-specific pTfh have been shown to correlate with neutralizing
69 antibodies in the context of infection and vaccination of several pathogens (17, 22-26). Although

70 pTfh responses have not been described in the context of SARS-CoV or MERS-CoV infection,
71 CD4 T-cell responses have been shown to be important in controlling SARS-CoV in mouse
72 models (27), and a recent study of a MERS-CoV vaccine in mice found that Tfh frequencies in
73 draining lymph nodes correlated with neutralizing antibodies (28).

74 Data on SARS-CoV-2-specific T follicular helper cell responses are also limited.
75 Thevarajan et al. was the first to report on pTfh frequencies in SARS-CoV-2, and found that
76 frequencies of total pTfh increased during acute infection (29). Since then, a few studies have
77 drawn a correlation between total CD4 T cell or total Tfh-like cell frequencies and antibody levels
78 (30, 31). Another study found increased expression of CXCR5 and ICOS, two Tfh markers, on
79 SARS-CoV-2-specific CD4 T-cells but did not examine pTfh responses directly (32). In deceased
80 donors with COVID-19, Kaneko et al. recently reported that BCL6-expression in germinal center
81 Tfh was lost within thoracic lymph nodes. This study suggests that Tfh response formation may
82 be impaired in severe SARS-CoV-2 infection (33), but how this affects the formation of antigen
83 specific Tfh responses is unclear.

84 The most direct examination of pTfh to date was conducted by Juno et al, where circulating
85 Tfh in the blood were defined as CD45RA⁻CXCR5⁺ CD4 T cells. They demonstrated a correlation
86 between S protein-specific pTfh and nAb, suggesting that Tfh responses are formed in mild
87 SARS-CoV-2 infection (34). However, these data leave several questions unanswered, including
88 at what point in convalescence these responses evolve and whether Tfh specific for other SARS-
89 CoV-2 proteins contribute to the formation of neutralizing antibodies. While this study was a useful
90 first glimpse at antigen-specific Tfh responses, it did not examine PD1 expression, a canonical
91 Tfh marker, and used the activation markers, Ox40 and CD25, to identify antigen-specific
92 responses, which have previously been shown include a high percentage of T regulatory cells
93 (35). It is also important to note that pTfh specificity does not necessarily correspond with
94 neutralizing antibody specificity. For example, in HIV infection and vaccination, intrastructural help
95 occurs, where CD4 T-cell responses to internal, structural proteins correlated with neutralizing

96 antibodies against the exterior, envelope protein (36, 37). These studies underscore the
97 importance of examining pTfh responses across the SARS-CoV-2 proteome.

98 Here, we report on SARS-CoV-2-specific CD4 T-cell responses to the membrane (M),
99 nucleocapsid (N), and spike (S) proteins studied longitudinally in 21 convalescent individuals. We
100 directly examined antigen-specific pTfh (CXCR5⁺PD1⁺ CD4 T cells) and observed correlations
101 between antigen-specific pTfh responses across all protein specificities and antibody
102 neutralization, with the strongest correlation observed for S protein-specific pTfh frequencies.
103 High magnitude SARS-CoV-2-specific pTfh responses (>5% activation of total pTfh population)
104 were only detected at the second convalescent visit, more than 30 days following symptom onset.
105 These data are the first to examine the kinetics of pTfh responses that arise after SARS-CoV-2
106 infection as well as the relationship between neutralizing antibodies and pTfh responses to the
107 SARS-CoV-2 M and N proteins. These results also suggest that pTfh formation may be delayed
108 in SARS-CoV-2 infection.

109

110 **Results:**

111 **SARS-CoV-2-specific CD4 T cells target the M, N, and S proteins in individuals recovered** 112 **from COVID-19 at their first convalescent visit.**

113 In 21 individuals recovered from COVID-19, we assessed the presence of T-cell
114 responses to the membrane (M), nucleocapsid (N), and spike (S) proteins of SARS-CoV-2 using
115 overlapping 20mer peptide pools spanning each protein. All but two of these individuals were
116 confirmed to have SARS-CoV-2 infection by PCR, and the two who were not PCR tested had a
117 known COVID-19 contact and detectable SARS-CoV-2-specific T-cell responses. While none of
118 these individuals required hospitalization, all experienced COVID-19 related symptoms, and a
119 majority (71%) reported a moderate severity of symptoms. T-cell responses were measured at
120 the first convalescent visit for each individual, which occurred an average of 22 days post-
121 symptom onset while the second visit was an average of 39 days post-symptom onset (**Table 1**).

122 We utilized two flow cytometry-based strategies: 1) upregulation of activation-induced markers
123 (AIM), and 2) production of effector molecules by intracellular cytokine staining (ICS). Gating
124 strategies for AIM and ICS in an unstimulated, negative control are shown in **S1 Fig**.

125 **Table 1: Patient demographics**

	Convalescent (N=21)	Healthy Control (N=10)
Age	40 (20, 76)	41 (30, 50)
Sex		
Female	38%	60%
Male	62%	40%
Days post-symptom onset*		
Visit 1	22 (12, 40)	NA
Visit 2	38 (26, 59)	NA
Days between visits*	14 (7, 27)	NA
Symptom severity		
Mild (1)	29% (6/21)	NA
Moderate (2)	71% (15/21)	NA
Severe (3)	0% (0/21)	NA

*Values reported as median with range in parentheses

126
127 Representative positive CD4 T-cell responses measured by each staining strategy are
128 shown in **Fig 1A** for AIM and in **Fig 1B** for ICS in one individual, CR8, who mounted CD4 T-cell
129 responses against all three SARS-CoV-2 proteins. At the first convalescent visit, we found that
130 57% (12/21) of individuals mounted a SARS-CoV-2-specific CD4 T-cell response by AIM and that
131 these CD4 responses targeted all three tested proteins with similar frequencies (**Fig 1C**).
132 Meanwhile, by ICS, 47% (10/21) of individuals had at least one SARS-CoV-2-specific CD4
133 response at this visit, with a similar distribution across the tested proteins (**Fig 1D**). As a control,
134 we also measured T cell responses to SARS-CoV-2 peptide pools in COVID-19 negative
135 individuals by assaying samples collected from healthy individuals before the COVID-19
136 pandemic. In the healthy controls tested, we detected three low magnitude ($\leq 0.17\%$), presumably
137 cross-reactive memory CD4 T-cell responses in two of the ten tested individuals (20%) in line with
138 previously published reports (8). Representative staining of an AIM-detected and an ICS-detected

139 response in healthy controls is shown in **S2A-B Fig**, with overall responder frequencies presented
140 in **S2C-D Fig**. Overall, our data show that nearly half of convalescent individuals mounted a
141 SARS-CoV-2 specific CD4 T-cell response as detected by both activation marker expression and
142 cytokine production.

143 While there was a weak correlation between the response magnitude for AIM and ICS for
144 each condition (**S3A Fig**), more responses were identified by upregulation of activation-induced
145 marker expression than by intracellular cytokine staining. There were 12 responses detected by
146 only AIM that were not positive on ICS, but only one response was detected by ICS only (**S3B Fig**).
147 These data show that a significant portion of CD4 responses detected in early convalescence were
148 not detected by cytokine (IFN γ , TNF α , or CD154) staining and highlight the increased sensitivity
149 of AIM for detecting total CD4 T-cell responses.

150

151 **SARS-CoV-2-specific peripheral T follicular helper cells are detected in convalescent** 152 **individuals.**

153 We directly measured antigen-specific pTfh responses by the upregulation of Ox40 and
154 PDL1 on CXCR5⁺PD1⁺ CD4 T cells (gating strategy shown in **S1 Fig**). Representative examples
155 of SARS-CoV-2-specific pTfh responses to the M, N, and S proteins are shown in **Fig 2A**. At the
156 first convalescent visit, occurring an average of 23 days post-symptom onset, we detected 6 total
157 pTfh responses in 4 of the 21 individuals tested (19%) and equally spread across each of the
158 three proteins (**Fig 2B**). These data indicate that only a minority of individuals have mounted
159 detectable SARS-CoV-2-specific pTfh responses early in convalescence. However, previous
160 studies on pTfh responses have rarely calculated responder rates, and, therefore, it is difficult to
161 conclude whether this responder frequency is atypical.

162 Meanwhile, none of the healthy controls tested had detectable SARS-CoV-2-specific pTfh
163 responses. This lack of pTfh responses in COVID negative individuals is not surprising, as pTfh
164 compose a minor population of the total CD4 T cells in the blood and pTfh responses induced by
165 other seasonal coronaviruses, if present, are likely to exist at very low, undetectable frequencies.
166 Additionally, the fact that these responses were only detected in convalescent individuals
167 bolsters our confidence that these pTfh responses were induced by recent SARS-CoV-2 infection
168 and do not represent cross-reactive, memory responses.

169
170 **SARS-CoV-2-specific pTfh frequencies across the M, N, and S proteins correlate with**
171 **antibody neutralization.**

172 Because pTfh are important for the development of an antibody response, we investigated
173 whether the frequency of SARS-CoV-2-specific pTfh correlated with antibody level and
174 neutralization at the first convalescent visit. We used two measurements of antibodies: The first
175 was the commercially available Abbott test that detects N protein-specific IgG. The second assay
176 measured antibody neutralization by luciferase expression and is likely a more biologically
177 relevant metric because neutralizing antibodies have been shown to correlate with protection in
178 preclinical studies (14, 15). For all three proteins, we see a similar level of significant correlation
179 between the antigen-specific pTfh frequency and N protein IgG titer (**Fig 3A**). However, we find
180 that pTfh frequencies across proteins differentially correlate with antibody neutralization (**Fig 3B**):
181 S protein-specific pTfh responses most strongly correlate with nAb ($p < 0.0001$, $r = 0.75$), followed
182 by M protein-specific ones ($p = 0.001$, $r = 0.66$), and finally N protein-specific pTfh ($p = 0.02$, $r =$
183 0.52). To ensure these correlations were specific to SARS-CoV-2-induced responses, we
184 quantified the frequency of total pTfh (CXCR5⁺PD1⁺). We did not see any correlation between the
185 overall frequency of pTfh and antibody levels or neutralization (**Fig 3C**). Taken together, these

186 data suggest that pTfh responses across SARS-CoV-2 proteins may contribute to the
187 development of more potent nAbs.

188
189 **SARS-CoV-2-specific peripheral T follicular helper responses increase over time in**
190 **convalescence.**

191 To better understand the kinetics of these pTfh responses, we assessed T-cell responses
192 in each of the convalescent individuals at a second, later visit, an average of 38 days post-
193 symptom onset (range: 26-59 days). pTfh response frequencies detected by AIM increased from
194 the first to second convalescent visit, where the overall pTfh responder rate went from 19% (4/21)
195 to 43% (9/21). This increase in responses over time is most obviously observed towards the M
196 protein where the CD4 T-cell response rate increased from 38% to 57% and the pTfh response
197 rate increased from 10% to 33% (**Fig 4A**). Additionally, M protein-specific CD4 T-cell and pTfh
198 response magnitudes by AIM trended up from the first to second visit ($p = 0.09$ and $p = 0.07$,
199 respectively), while other antigen-specific subsets appeared at similar magnitudes at both
200 timepoints (**Fig 4B**).

201 At the first visit timepoint, there were no pTfh responses with a magnitude higher than 5%
202 frequency. Meanwhile, at the second visit, five such SARS-CoV-2-specific pTfh responses were
203 detected in four individuals. For these four individuals, the first visit took place an average of 17
204 days post-symptom onset, and the second visit took place an average of 32.5 days post-symptom
205 onset. In the case of CR21, a robust M protein-specific pTfh response arose over just seven days.
206 These antigen stimulations are shown for both Visit 1 and Visit 2 in **Fig 4C**, and the number of
207 days between visits is indicated between the top and bottom panels. Of these responses, only
208 one was detected at the first visit (CR11, S protein). These responses suggest that SARS-CoV-
209 2-specific pTfh continue to increase over time during convalescence.

210
211 **Discussion:**

212 In this study, we longitudinally examined the CD4 T-cell responses targeting the major
213 SARS-CoV-2 structural proteins, M, N, and S, in 21 convalescent individuals by measuring the
214 expression of activation marker and the production of effector cytokines. We found that at the first
215 convalescent visit, antigen-specific pTfh responses could be detected against all three proteins
216 and that the frequency of antigen-specific pTfh in these individuals correlated with nAb, albeit to
217 varying degrees. We also found that pTfh responses increase over time in convalescence and
218 that truly robust pTfh responses (>5% frequency) were only detected at a second, later visit.

219 The relative weakness of the correlation between N protein-specific pTfh frequency and
220 antibody neutralization compared to the M and S proteins may relate back to the structure of
221 SARS-CoV-2. Both the spike and membrane proteins have portions that are located exteriorly,
222 while the nucleocapsid protein is found exclusively internally. Collectively, these data suggest that
223 pTfh responses induced against different SARS-CoV-2 proteins may not be equally effective in
224 aiding B cells and bolsters the foundation for several vaccine strategies currently in testing which
225 only include the Spike protein. In fact, many of these vaccines have reported levels of antibodies
226 similar to those seen in natural SARS-CoV-2 infection and mild disease, which may be a result of
227 focusing the pTfh response on the S protein (12, 38). However, as prior studies have shown CD4
228 T cells across different protein specificities may contribute to nAb induction (36, 37), future studies
229 should work to ascertain the level to which M and N protein-specific pTfh responses contribute to
230 the formation of neutralizing antibodies. It is possible that pTfh responses across different protein
231 specificities all play a synergistic role in the development of nAb.

232 Meanwhile, the observed increase in pTfh responses over time suggests that pTfh
233 response formation may be delayed in SARS-CoV-2 infection. A study of influenza vaccination
234 showed that pTfh responses peaked seven days after vaccine administration (25); meanwhile, a
235 longitudinal study of pTfh in dengue virus infection found that the frequency of antigen-specific
236 pTfh decreased from the time of acute infection (22). In comparison with these studies, it appears
237 that pTfh response formation in SARS-Cov-2 infection continues well into convalescence as the

238 second visit for all individuals assessed in this study occurred an average of 38 days following
239 symptom onset. A delay in pTfh response formation could be due to the T-cell dysfunction that
240 occurs in SARS-CoV-2 infection. Many groups have described significant T-cell dysfunction in
241 acute SARS-CoV-2 infection (4, 5, 39), and our group has recently illustrated that this dysfunction
242 is sustained during convalescence, even in non-hospitalized individuals (6). These high
243 magnitude pTfh responses could also be the result of persistent antigen exposure, as several
244 groups have reported prolonged detection of SARS-CoV-2 by PCR (40, 41). Future studies would
245 ideally delve deeper by examining additional relevant cytokines, like IL4, IL13, and IL21, and
246 combine activation marker and cytokine staining to allow for comprehensive functional analysis
247 of these impressive pTfh responses arising later in convalescence.

248 It is also important to note that not all responses initially detected at the first visit were
249 observed at the second visit, as illustrated by the full CD4 and pTfh response mapping by AIM
250 and ICS (**S4A-C Fig**). When considering responses detected at either timepoint, 17/21 (81%) of
251 individuals mounted a SARS-CoV-2-specific CD4 T-cell response by AIM (**S4D Fig**), and CD4
252 response were detected in 13/21 (62%) of individuals by ICS (**S4E Fig**). In fact, 43% T-cell
253 responses detected by AIM were found at only one of the two tested timepoints. Even so, the
254 responder frequencies detected at each visit (57% at visit 1 and 62% at visit 2, by AIM) are lower
255 than what other recent studies have published, where SARS-CoV-2-specific T-cell responses were
256 detected in 80-100% of individuals tested (8, 10). One reason for this is that we applied a stringent
257 positivity criteria where responses were considered positive when three times over background
258 and significant by fisher's exact (p value < 0.0001), based on optimization studies conducted by
259 the HIV Vaccine Trials Network (42). For example, for CD4 T cell responses by ICS, our responder
260 frequency at the first visit was 48% (10/21), but if using three times the background, the CD4

261 responder rate is 76% (16/21). This strategy likely decreases our false positive rate but may also
262 contribute to the discrepancy between our data and previously published studies.

263 These data further our understanding of CD4 T-cell responses, particularly pTfh
264 responses, against SARS-CoV-2. Our study directly measures SARS-CoV-2-specific pTfh
265 responses to three major structural proteins, M, N, and S. We clearly demonstrate that SARS-
266 CoV-2-specific pTfh responses that arise early in convalescence strongly correlate with antibody
267 neutralization and that S protein-specific responses most closely relate to antibody neutralization.
268 But, we also show that pTfh responses against other SARS-CoV-2 proteins correlate with
269 antibody neutralization, indicating a possible role for intrastructural help. Finally, in measuring
270 these responses over time, we observe the emergence of several high magnitude responses
271 more than a month following symptom onset, suggesting that pTfh response formation may be
272 delayed in SARS-CoV-2 infection.

273

274 **Methods and Materials**

275 **Ethics statement:** All patients included in this study were adults and recruited from the University
276 of Alabama at Birmingham (UAB) HIV care clinic, also known as the 1917 clinic, after obtaining
277 written, informed consent and approval from the IRB-160125005 at UAB.

278 **Patient Samples:** Cryopreserved PBMC samples for T-cell assays and plasma samples for
279 antibody assays were acquired through the UAB COVID Enterprise Biorepository. All samples
280 were obtained with patient consent under the appropriate IRB guidelines. Patient demographic
281 information is shown in **Table 1**. Paired Visit 1 and Visit 2 PBMC samples from 21 individuals who
282 had recovered from COVID-19 were assessed in this study. Clinical data from these individuals
283 were retrieved from the Enterprise Biorepository REDCap database (43). All tested individuals
284 were symptomatic, but none were hospitalized during the course of their illness. Symptom severity
285 was quantified using a self-reported severity score on a scale of 1 to 3, where 1 represented no

286 interference in daily life, 2 a moderate impact on daily life, and 3 a significant decrease in quality
287 of life due to symptoms. A majority of individuals reported moderate severity (71%, 15/21), and a
288 minority reported mild severity of symptoms (29%, 6/21). None reported severe symptoms.
289 Additionally, all but two had a positive SARS-CoV-2 nasopharyngeal swab. The two individuals
290 who did not have a PCR test completed had a known COVID contact, were symptomatic, and
291 had detectable T-cell responses. Clinical data PBMCs from 10 healthy donors (all collected prior
292 to the COVID-19 pandemic) were assessed for T-cell responses in parallel.

293 **Peptide pools:** Overlapping peptides spanning the SARS-CoV-2 M, N, and S proteins (NCBI
294 reference number MN985325.1) were designed as 20mers overlapping by 10 amino acids which
295 has previously been shown to effectively detect CD4 T-cell responses (44, 45). Peptides were
296 synthesized by New England Peptide in a 96-well plate format.

297 **Flow cytometry:** For activation-induced marker staining (AIM), cells were thawed and stimulated
298 with SARS-CoV-2 peptide pools for each of the M, N, and S proteins. An unstimulated, negative
299 control and an SEB stimulated, positive control were included for each sample. Co-stimulatory
300 anti-CD28 and anti-CD49d were added (BD Pharmingen). After an 18 hour incubation at 37°C,
301 cells were washed with FACS wash (2% FBS in PBS), stained with CCR7- PercpCy5.5 at 37°C
302 for 20 min, washed, and then stained with the following antibodies: CD4-Pe610, CD3-A780, CD8-
303 FITC, CD14-A700, CD19-A700, Ox40-PeCy7, PDL1-PE, CXCR5-BV421, PD1-BV785, CD45RA-
304 BV510, CD137-BV650, CD69-BUV737, and Dead cell dye-UV. Cells were then washed and fixed
305 in 2% formaldehyde. Events were collected on a BD FACSymphony A3 within 24 hours and
306 analyzed using FlowJo software (v10).

307 Intracellular staining (ICS) experiments were set up in parallel with the AIM staining
308 experiments and performed similarly, with a few notable exceptions. CD107a-FITC was added
309 with the co-stimulatory antibody mix; Monensin and Brefeldin A (BD Bioscience) were added after
310 1 hour. Cells were incubated for 12 hours in total, instead of 18. Staining was conducted in three
311 steps: 1) Surface marker staining for 30 min at 4°C with Dead cell dye-UV, CD3-A780, CD4-

312 BV785, CD8-V500, CD14-PercpCy5.5, and CD19-PercpCy5.5. 2) Permeabilization with
313 CytoFix/CytoPerm solution (BD Biosciences) for 20min at 4°C. 3) Intracellular staining for 30 min
314 at 4°C with IFN γ -A700, TNF α -PeCy7, and CD154-APC. CD154 was plotted against IFN γ .
315 Additional details regarding the antibodies used in both the AIM and ICS assays can be found in
316 **S1 Table**, and the gating strategies for AIM and ICS in an unstimulated, negative control are
317 shown in **S1 Fig**.

318 **Antibody assays:** Plasma samples from the first time point for all 21 individuals were tested for
319 SARS-CoV-2-specific antibodies. The Abbott Architect assay was used to detect immunoglobulin
320 G (IgG) reactivity to the SARS-CoV-2 nucleocapsid protein (46). The IgG quantity is reported as
321 a calculated index specimen/calibrator ratio, and values over 1.4 were considered positive for N
322 protein IgG. Manufacturer-reported specificity of this assay is 99.6% (99.1%-99.9%).

323 Antibody neutralization assays were conducted as previously described (47). Briefly, the
324 SARS-CoV-2 Spike (Wuhan 1, with a 19 amino acid cytoplasmic tail deletion) was pseudotyped
325 onto an HV-1 nanoluciferase reporter backbone by co-transfection in HEC 293T cells.
326 Pseudovirus was incubated with five-fold serial dilutions of patient plasma and then used to infect
327 1.5×10^4 293T clone 13 cells expressing ACE2. Two days post-infection, cells were washed with
328 PBS, lysed, and nanoluciferase activity was determined according to manufacturer's instructions
329 (Nano-Glo® Luciferase Assay System). Luciferase activity in wells with virus and no patient
330 plasma were set to 100%, and the dilution of plasma at which luminescence was reduced to 50%
331 (ID50) was calculated.

332 **Statistical analysis:** Comparisons between paired visit 1 and visit 2 magnitudes were conducted
333 by Wilcoxon signed-rank tests. All correlations were determined by Spearman Rank tests, with
334 the exception of Supplemental Figure 2A, where multiple measurements were plotted for each
335 individual (across the three proteins) and therefore a generalized linear mixed effect model
336 accounting for multiple measurements per individual was employed. In Figure 3, all axes were

337 transformed using $\log_{10}(x+1)$ to allow for visualization of zeros, and correlations were determined
338 with untransformed data.

339

340 **Figure Captions:**

341 **Fig 1: SARS-CoV-2-specific CD4 T cells target the M, N, and S proteins in individuals**
342 **recovered from COVID-19 at their first convalescent visit.** Representative examples of CD4
343 responses in CR8 to the M, N, and S protein peptide pools as detected by upregulation of
344 activation-induced markers, Ox40 and PDL1 **(A)** and by IFN γ in intracellular cytokine staining **(B)**.
345 Responder frequency of CD4 responses to any SARS-CoV-2 protein and to the M, N, and S
346 proteins individually by AIM **(C)** and ICS **(D)**.

347

348 **Fig 2: SARS-CoV-2-specific peripheral T follicular helper cells are detected at the first visit**
349 **in in 4 out of 21 convalescent individuals. (A)** Representative examples of antigen-specific
350 pTfh (CD4⁺PD1^{hi}CXCR5⁺) detected upon stimulation with SARS-CoV-2 the M, N, and S protein
351 peptides for Visit 1 across three individuals (CR8, CR11, and CR13, respectively). Negative
352 control of unstimulated cells shown in the top row. **(B)** Frequency of individuals mounting a
353 positive pTfh response at their first visit to any SARS-CoV-2 protein and to the M, N, and S protein
354 peptide pools.

355

356 **Fig 3: SARS-CoV-2-specific pTfh frequencies across the M, N, and S proteins correlate with**
357 **antibody neutralization. (A)** Correlations between N protein IgG titers and pTfh frequencies
358 towards the M, N, and S proteins. **(B)** Correlations between antibody neutralization (ID50, dilution
359 of plasma at which luminescence was reduced to 50%) and pTfh frequencies. **(C)** Correlations
360 between the total pTfh frequency and antibody titer and neutralization. (All correlations
361 represented by a linear regression line. Axes are transformed by $\log_{10}(x+1)$ to allow for

362 visualization of 0s. Statistics were determined by a Spearman Correlation test. Points are colored
363 for PTID.)

364

365 **Fig 4: Robust SARS-COV-2-specific pTfh responses are only detected at the second**
366 **convalescent visit. (A)** Paired convalescence visit 1 and visit 2 CD4 and pTfh response
367 magnitudes by AIM. **(B)** Paired CD4 and pTfh response magnitudes for AIM. **(C)** Flow plots for
368 both the first (top) and second (bottom) convalescent visit of individuals where robust pTfh
369 responses (>5%) developed. Unstimulated negative control shown for each. SARS-CoV-2 protein
370 to which response is directed is listed next to the PTID in parentheses. (N=21, P values for
371 magnitude comparisons determined by a paired Wilcoxon Signed-Rank Test.)

372

373 **Acknowledgments**: We would like to acknowledge the following funding sources: internal
374 funding from the University of Alabama at Birmingham School and Department of Medicine and
375 F30AI140829 (SB). We would also like to thank all those who helped process samples, especially
376 Sarah Sterrett.

377 **References**

- 378 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
379 Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-33.
- 380 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus
381 Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-20.
- 382 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019
383 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.
- 384 4. De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, et al. Marked T cell
385 activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.
386 *Nat Commun.* 2020;11(1):3434.
- 387 5. Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, et al. Immunological and inflammatory profiles in
388 mild and severe cases of COVID-19. *Nat Commun.* 2020;11(1):3410.
- 389 6. Files JK, Boppana S, Perez MD, Sarkar S, Lowman KE, Qin K, et al. Sustained Cellular Immune
390 Dysregulation in Individuals Recovering from SARS-CoV-2 Infection. *Journal of Clinical Investigations.*
391 2020; :in press.
- 392 7. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype and
393 kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci*
394 *Immunol.* 2020;5(48).
- 395 8. Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in
396 healthy donors and patients with COVID-19. *Nature.* 2020.
- 397 9. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell
398 immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature.* 2020.
- 399 10. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell
400 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
401 *Cell.* 2020;181(7):1489-501 e15.
- 402 11. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
403 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase
404 1/2, single-blind, randomised controlled trial. *Lancet.* 2020.
- 405 12. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA
406 Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med.* 2020.
- 407 13. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2
408 Recombinant Spike Protein Nanoparticle Vaccine. *N Engl J Med.* 2020.
- 409 14. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-CoV-2
410 infection protects against rechallenge in rhesus macaques. *Science.* 2020;369(6505):812-7.
- 411 15. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine
412 protection against SARS-CoV-2 in rhesus macaques. *Science.* 2020;369(6505):806-11.
- 413 16. Pissani F, Streeck H. Emerging concepts on T follicular helper cell dynamics in HIV infection.
414 *Trends Immunol.* 2014;35(6):278-86.
- 415 17. Heit A, Schmitz F, Gerdt S, Flach B, Moore MS, Perkins JA, et al. Vaccination establishes clonal
416 relatives of germinal center T cells in the blood of humans. *J Exp Med.* 2017;214(7):2139-52.
- 417 18. Moysi E, Pallikkuth S, De Armas LR, Gonzalez LE, Ambrozak D, George V, et al. Altered immune
418 cell follicular dynamics in HIV infection following influenza vaccination. *J Clin Invest.* 2018;128(7):3171-
419 85.
- 420 19. Vella LA, Buggert M, Manne S, Herati RS, Sayin I, Kuri-Cervantes L, et al. T follicular helper cells in
421 human efferent lymph retain lymphoid characteristics. *J Clin Invest.* 2019;129(8):3185-200.

- 422 20. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, et al. CXCR5 expressing human central
423 memory CD4 T cells and their relevance for humoral immune responses. *J Immunol*. 2011;186(10):5556-
424 68.
- 425 21. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating precursor CCR7(lo)PD-1(hi)
426 CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen
427 reexposure. *Immunity*. 2013;39(4):770-81.
- 428 22. Haltaufderhyde K, Srikiatkachorn A, Green S, Macareo L, Park S, Kalayanarooj S, et al.
429 Activation of Peripheral T Follicular Helper Cells During Acute Dengue Virus Infection. *J Infect Dis*.
430 2018;218(10):1675-85.
- 431 23. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, et al. Human
432 circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly
433 neutralizing HIV antibody responses. *Immunity*. 2013;39(4):758-69.
- 434 24. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest
435 cross-neutralizing antibody response to HIV-1. *PLoS Pathog*. 2011;7(1):e1001251.
- 436 25. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, et al. Induction of
437 ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. *Sci Transl*
438 *Med*. 2013;5(176):176ra32.
- 439 26. Sterrett S, Peng BJ, Burton RL, LaFon DC, Westfall AO, Singh S, et al. Peripheral CD4 T follicular
440 cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic
441 antibody responses in younger individuals. *Vaccine*. 2020;38(7):1778-86.
- 442 27. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, et al. Cellular immune responses
443 to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+
444 T cells are important in control of SARS-CoV infection. *J Virol*. 2010;84(3):1289-301.
- 445 28. George PJ, Tai W, Du L, Lustigman S. The Potency of an Anti-MERS Coronavirus Subunit Vaccine
446 Depends on a Unique Combinatorial Adjuvant Formulation. *Vaccines (Basel)*. 2020;8(2).
- 447 29. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of
448 concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nat*
449 *Med*. 2020;26(4):453-5.
- 450 30. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-Specific Humoral
451 and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity*. 2020;52(6):971-7 e3.
- 452 31. Gong F, Dai Y, Zheng T, Cheng L, Zhao D, Wang H, et al. Peripheral CD4+ T cell subsets and
453 antibody response in COVID-19 convalescent individuals. *J Clin Invest*. 2020.
- 454 32. Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, et al. SARS-CoV-2-specific T cells exhibit
455 phenotypic features of robust helper function, lack of terminal differentiation, and high proliferative
456 potential. *Cell Rep Med*. 2020:100081.
- 457 33. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. The Loss of Bcl-6
458 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19. *SSRN*.
459 2020:3652322.
- 460 34. Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular
461 helper T cell responses in recovered patients with COVID-19. *Nat Med*. 2020.
- 462 35. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative analysis of
463 activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. *PLoS*
464 *One*. 2017;12(10):e0186998.
- 465 36. Ranasinghe S, Soghoian DZ, Lindqvist M, Ghebremichael M, Donaghey F, Carrington M, et al.
466 HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
467 *J Virol*. 2015;90(5):2208-20.

- 468 37. Storcksdieck genannt Bonsmann M, Niezold T, Temchura V, Pissani F, Ehrhardt K, Brown EP, et
469 al. Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells. *J Immunol.*
470 2015;195(10):4861-72.
- 471 38. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
472 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase
473 1/2, single-blind, randomised controlled trial. *Lancet.* 2020;396(10249):467-78.
- 474 39. Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. Deep immune profiling
475 of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science.*
476 2020;369(6508).
- 477 40. Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, et al. Prolonged Persistence of SARS-CoV-2 RNA in
478 Body Fluids. *Emerg Infect Dis.* 2020;26(8):1834-8.
- 479 41. Wu J, Liu X, Liu J, Liao H, Long S, Zhou N, et al. Coronavirus Disease 2019 Test Results After
480 Clinical Recovery and Hospital Discharge Among Patients in China. *JAMA Netw Open.*
481 2020;3(5):e209759.
- 482 42. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, et al. Optimization and validation
483 of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by
484 vaccination. *J Immunol Methods.* 2007;323(1):39-54.
- 485 43. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium:
486 Building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.
- 487 44. Tobery TW, Wang S, Wang XM, Nepper MP, Jansen KU, McClements WL, et al. A simple and
488 efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a
489 modified ELISpot assay. *J Immunol Methods.* 2001;254(1-2):59-66.
- 490 45. Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, et al. Comparison of
491 overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. *J Immunol Methods.*
492 2003;275(1-2):19-29.
- 493 46. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance
494 Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin*
495 *Microbiol.* 2020;58(8).
- 496 47. Schmidt F, Weisblum Y, Muecksch F, Hoffmann HH, Michailidis E, Lorenzi JCC, et al. Measuring
497 SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *bioRxiv.* 2020.
498

499 **Supporting information**

500 **Supplemental Figure 1: Flow cytometry gating strategies. (A)** Gating strategy for CD4 T cell
501 and pTfh by activation-induced marker (AIM). **(B)** Gating strategy for CD4 T cell staining by
502 intracellular cytokine staining.

503
504 **Supplemental Figure 2: SARS-CoV-2-reactive CD4 T cells are infrequently detected in**
505 **COVID negative individuals.** Representative examples of CD4 T-cell responses detected in
506 COVID negative individuals by upregulation of activation-induced markers **(A)** and by intracellular
507 cytokine staining **(B)** upon stimulation by SARS-CoV-2 N protein peptide pool. Responder
508 frequency of CD4 responses to any SARS-CoV-2 protein and to the M, N, and S proteins
509 individually by AIM **(C)** and ICS **(D)**.

510
511 **Supplemental Figure 3: Upregulation of activation markers detected a broader range of**
512 **SARS-CoV-2-specific CD4 T-cell responses. (A)** Correlation between response magnitude by
513 AIM versus response magnitude by ICS. Statistics determined by mixed effect model accounting
514 for multiple protein stimulations per individual. and correlation represented by linear regression
515 line. Data transformed by $\log_{10}(x+1)$ to allow for visualization of 0s. **(B)** Number and frequency
516 of responses that were positive or negative by AIM and ICS. Total responses considered was 63
517 (3 proteins per 21 individuals).

518
519 **Supplemental Figure 4: Summary of all responses detected across two convalescent**
520 **visits. (A-C)** Response summary for CD4 T cells by activation-induced marker staining, for pTfh
521 by activation-induced marker staining, and for CD4 T cells by intracellular cytokine staining,
522 respectively. Blue-filled cells indicate a positive response; white cells indicate a negative
523 response. **(D)** Responder frequency by AIM across the two visits (positive at either visit) overall
524 and to each protein. **(E)** Responder frequency by ICS across the two visits (positive at either visit).

Figure 1: SARS-CoV-2-specific CD4 T cells target the M, N, and S proteins in individuals recovered from COVID-19 at their first convalescent visit. Representative examples of CD4 responses in CR8 to the M, N, and S protein peptide pools as detected by upregulation of activation-induced markers, Ox40 and PDL1 (**A**) and by IFN γ in intracellular cytokine staining (**B**). Responder frequency of CD4 responses to any SARS-CoV-2 protein and to the M, N, and S proteins individually by AIM (**C**) and ICS (**D**).




Figure 2: SARS-CoV-2-specific peripheral T follicular helper cells are detected at the first visit in 4 out of 21 convalescent individuals. (A) Representative examples of antigen-specific pTfh (CD4⁺PD1^{hi}CXCR5⁺) detected upon stimulation with SARS-CoV-2 the M, N, and S protein peptides for Visit 1 across three individuals (CR8, CR11, and CR13, respectively). Negative control of unstimulated cells shown in the top row. **(B)** Frequency of individuals mounting a positive pTfh response at their first visit to any SARS-CoV-2 protein and to the M, N, and S protein peptide pools.




Figure 3: SARS-CoV-2-specific pTfh frequencies across the M, N, and S proteins correlate with antibody neutralization. (A) Correlations between N protein IgG titers and pTfh frequencies towards the M, N, and S proteins. **(B)** Correlations between antibody neutralization (ID50, dilution of plasma at which luminescence was reduced to 50%) and pTfh frequencies. **(C)** Correlations between the total pTfh frequency and antibody titer and neutralization. (All correlations represented by a linear regression line. Axes are transformed by $\log_{10}(x+1)$ to allow for visualization of 0s. Statistics determined by a Spearman Correlation test. Points are colored for PTID.)




Figure 4: Robust SARS-COV-2-specific pTfh responses are only detected at the second convalescent visit. (A) Paired convalescence visit 1 and visit 2 CD4 and pTfh response magnitudes by AIM. (B) Paired CD4 and pTfh response magnitudes for AIM. (C) Flow plots for both the first (top) and second (bottom) convalescent visit of individuals where robust pTfh responses (>5%) developed. Unstimulated negative control shown for each. SARS-CoV-2 protein to which response is directed is listed next to the PTID in parentheses. (N=21, P values for magnitude comparisons determined by a paired Wilcoxon Signed-Rank Test.)

